Home LiteratureArticle Details
PMID: 12677558 Published · ppublish English Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

American journal of human genetics ·Vol. 72 ·No. 5 ·2003-05-00 ·Pages 1117-30

Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjäkoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF

Abstract

Germline mutations in BRCA1 and BRCA2 confer high risks of breast and ovarian cancer, but the average magnitude of these risks is uncertain and may depend on the context. Estimates based on multiple-case families may be enriched for mutations of higher risk and/or other familial risk factors, whereas risk estimates from studies based on cases unselected for family history have been imprecise. We pooled pedigree data from 22 studies involving 8,139 index case patients unselected for family history with female (86%) or male (2%) breast cancer or epithelial ovarian cancer (12%), 500 of whom had been found to carry a germline mutation in BRCA1 or BRCA2. Breast and ovarian cancer incidence rates for mutation carriers were estimated using a modified segregation analysis, based on the occurrence of these cancers in the relatives of mutation-carrying index case patients. The average cumulative risks in BRCA1-mutation carriers by age 70 years were 65% (95% confidence interval 44%-78%) for breast cancer and 39% (18%-54%) for ovarian cancer. The corresponding estimates for BRCA2 were 45% (31%-56%) and 11% (2.4%-19%). Relative risks of breast cancer declined significantly with age for BRCA1-mutation carriers (P trend.0012) but not for BRCA2-mutation carriers. Risks in carriers were higher when based on index breast cancer cases diagnosed at <35 years of age. We found some evidence for a reduction in risk in women from earlier birth cohorts and for variation in risk by mutation position for both genes. The pattern of cancer risks was similar to those found in multiple-case families, but their absolute magnitudes were lower, particularly for BRCA2. The variation in risk by age at diagnosis of index case is consistent with the effects of other genes modifying cancer risk in carriers.

MeSH Terms
Adult Age Distribution Aged Breast Neoplasms/epidemiology,genetics Cohort Studies Family Female Genes, BRCA1 Genes, BRCA2 Genetic Testing/statistics & numerical data Global Health Heterozygote Humans Incidence Male Middle Aged Mutation Ovarian Neoplasms/epidemiology,genetics Pedigree Risk Risk Assessment
Authors & Affiliations
33 authors, click to expand affiliations / ORCID
Antoniou A
Cancer Research U.K. Genetic Epidemiology Unit, Department of Public Health, University of Cambridge, Cambridge, United Kingdom.
Pharoah P D P
Narod S
Risch H A
Eyfjord J E
Hopper J L
Loman N
Olsson H
Johannsson O
Borg A
Pasini B
Radice P
Manoukian S
Eccles D M
Tang N
Olah E
Anton-Culver H
Warner E
Lubinski J
Gronwald J
Gorski B
Tulinius H
Thorlacius S
Eerola H
Nevanlinna H
Syrjäkoski K
Kallioniemi O-P
Thompson D
Evans C
Peto J
Lalloo F
Evans D G
Easton D F
References (43)
43 references, click to expand
  1. Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group.
    Stat Med. 1991 Jul;10(7):1025-35 PMID: 1652152
  2. Programs for Pedigree Analysis: MENDEL, FISHER, and dGENE.
    Genet Epidemiol. 1988;5(6):471-2 PMID: 3061869
  3. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.
    Am J Hum Genet. 1993 Apr;52(4):678-701 PMID: 8460634
  4. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
    Lancet. 1994 Mar 19;343(8899):692-5 PMID: 7907678
  5. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
    Science. 1994 Oct 7;266(5182):66-71 PMID: 7545954
  6. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
    Am J Hum Genet. 1995 Jan;56(1):265-71 PMID: 7825587
  7. Genetic epidemiology of early onset breast cancer.
    J Med Genet. 1994 Dec;31(12):944-9 PMID: 7891376
  8. Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation.
    Nat Genet. 1995 Dec;11(4):428-33 PMID: 7493024
  9. Identification of the breast cancer susceptibility gene BRCA2.
    Nature. 1995 Dec 21-28;378(6559):789-92 PMID: 8524414
  10. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
    Nat Genet. 1996 Mar;12(3):309-11 PMID: 8589723
  11. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.
    Nat Genet. 1996 Mar;12(3):333-7 PMID: 8589730
  12. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene.
    Nat Genet. 1997 Jan;15(1):103-5 PMID: 8988179
  13. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population.
    Am J Hum Genet. 1997 Feb;60(2):313-9 PMID: 9012404
  14. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
    N Engl J Med. 1997 May 15;336(20):1401-8 PMID: 9145676
  15. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
    Am J Hum Genet. 1998 Mar;62(3):676-89 PMID: 9497246
  16. BRCA1 mutations in southern England.
    Br J Cancer. 1998 Jun;77(12):2199-203 PMID: 9649133
  17. Population-based study of risk of breast cancer in carriers of BRCA2 mutation.
    Lancet. 1998 Oct 24;352(9137):1337-9 PMID: 9802270
  18. Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.
    J Natl Cancer Inst. 1998 Dec 2;90(23):1824-9 PMID: 9839523
  19. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat.
    Am J Hum Genet. 1999 May;64(5):1371-7 PMID: 10205268
  20. Prevalence of mutations in the BRCA1 gene among Chinese patients with breast cancer.
    J Natl Cancer Inst. 1999 May 19;91(10):882-5 PMID: 10340909
  21. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.
    J Natl Cancer Inst. 1999 Jun 2;91(11):943-9 PMID: 10359546
  22. BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer.
    Br J Cancer. 1999 Jan;79(1):34-9 PMID: 10408690
  23. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer.
    J Natl Cancer Inst. 1999 Jul 21;91(14):1241-7 PMID: 10413426
  24. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):741-7 PMID: 10498392
  25. Risk models for familial ovarian and breast cancer.
    Genet Epidemiol. 2000 Feb;18(2):173-90 PMID: 10642429
  26. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
    Hum Mutat. 1998;12(3):215 PMID: 10660329
  27. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Am J Hum Genet. 2000 Apr;66(4):1259-72 PMID: 10739756
  28. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary.
    Int J Cancer. 2000 Jun 1;86(5):737-40 PMID: 10797299
  29. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer.
    Eur J Cancer. 2000 Jun;36(10):1200-8 PMID: 10882857
  30. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
    J Natl Cancer Inst. 2000 Sep 20;92(18):1529-31 PMID: 10995809
  31. Extension of the lod score: the mod score.
    Adv Genet. 2001;42:115-24 PMID: 11037317
  32. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Br J Cancer. 2000 Nov;83(10):1301-8 PMID: 11044354
  33. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.
    Am J Hum Genet. 2001 Feb;68(2):410-9 PMID: 11170890
  34. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Am J Hum Genet. 2001 Mar;68(3):700-10 PMID: 11179017
  35. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6 PMID: 11248061
  36. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73 PMID: 11352856
  37. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study.
    Genet Epidemiol. 2001 Jul;21(1):1-18 PMID: 11443730
  38. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history.
    Cancer Res. 2001 Jul 15;61(14):5420-4 PMID: 11454686
  39. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23 PMID: 11504767
  40. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives.
    Pharmacogenetics. 2001 Oct;11(7):635-8 PMID: 11668223
  41. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer.
    Breast Cancer Res. 2002;4(1):R2 PMID: 11879560
  42. Variation in BRCA1 cancer risks by mutation position.
    Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):329-36 PMID: 11927492
  43. On the use of familial aggregation in population-based case probands for calculating penetrance.
    J Natl Cancer Inst. 2002 Aug 21;94(16):1221-6 PMID: 12189225
Article Info
Journal
American journal of human genetics
Abbr.
Am J Hum Genet
ISSN
0002-9297
Published
2003-05-00
Epub
2003-00-03
Pages
1117-30
Language
English
Region
United States
NLM ID
0370475
PMCID
PMC1180265
Subset
IM
Grants
NCI NIH HHS · R01 CA063682 · United States
NCI NIH HHS · 1R01 CA81203 · United States
NCI NIH HHS · R01 CA63682 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]